TABLE 4.

Adverse events^∗.

			Antibiotic-specific adverse events leading to treatment modification (n = 60)
	Total patients (n = 192)	Total frequency of adverse events (n = 319)	Clarithromycin (n = 4) (199 patients)	Azithromycin (n = 3) (61 patients)	Amikacin (n = 26) (218 patients)	Imipenem (n = 3) (67 patients)	Linezolid (n = 9) (38 patients)	Tigecycline (n = 15) (53 patients)
Gastrointestinal distress	79(41.1)	143(44.8)	4	3	4	0	4	14
Diarrhea	15(7.8)	22(6.9)	0	0	0	0	0	0
Abdominal pain	13(6.8)	25(7.8)	1	1	0	0	1	0
Nausea	35(18.2)	66(20.7)	1	2	4	0	2	10
Vomiting	16(8.3)	30(9.4)	2	0	0	0	1	4
Dizziness	7(2.9)	15(4.7)	0	0	0	0	0	0
Ototoxicity	11(5.7)	15(4.7)	0	0	14	0	0	0
Nephrotoxicity	20(10.4)	34(10.7)	0	0	5	0	0	0
Hepatotoxicity	9(4.7)	15(4.7)	0	0	0	0	0	1
Hematologic toxicity	11(5.7)	26(8.2)	0	0	0	1	5	0
Leukopenia	5(2.6)	11(3.4)	0	0	0	1	2	0
Thrombocytopenia	2(1.0)	5(1.6)	0	0	0	0	2	0
Anemia	4(2.1)	10(3.13)	0	0	0	0	1	0
Insomnia	3(1.6)	6(1.9)	0	0	0	0	0	0
Fever	3(1.6)	5(1.6)	0	0	0	0	0	0
Headache	14(7.3)	22(6.9)	0	0	0	0	0	0
Myoclonus	3(1.6)	4(1.3)	0	0	0	0	0	0
Agitation	3(1.6)	3(0.9)	0	0	0	1	0	0
Taste alteration	10(5.2)	11(3.4)	0	0	0	0	0	0
Allergic reactions	19(9.9)	20(6.3)	0	0	3	1	0	0

^∗The patients affected by the adverse event listed are enumerated. Notably, a single patient is often affected by more than one event. Those antibiotics, which most frequently cause events that necessitates treatment modification, are listed.